Skip to main content

Table 1 General characteristics of 376 patients with undetectable HIV-RNA switching to dual therapy

From: Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study

  N (%) Median (IQ range)
Male gender 286 (76.1)  
Age   50 (45–55)
Non-Italian origin 38 (10.1)  
Years on cART   13 (7–16)
IDU as risk factor 98 (26.1)  
AIDS diagnosis 127 (33.8)  
N. of prev. regimens   5 (3–9)
CD4+ nadir   123 (46–243)
Baseline CD4+ count   534 (341–701)
HCV co-infection 123 (32.7)  
Prev. GRT for VF 238 (63.3)  
Switch to PI/r
 ATV/r 69 (18.4)  
 DRV/r 237 (63.0)
 LPV/r 70 (18.6)
Switch to second drug
 ETR 62 (16.5)  
 RAL 202 (53.7)
 MVC 65 (17.3)
 3TC 23 (6.1)
 TDF 24 (6.4)
  1. Abbreviations: cART combined antiretroviral therapy, IDU injecting drug use, HCV hepatitis C virus, GRT genotypic resistance test, VF virological failure, PI/rit ritonavir-boosted protease inhibitor, ATV/r atazanavir/ritonavir, DRV/r darunavir/ritonavir, LPV/r lopinavir/ritonavir, ETR etravirine, RAL raltegravir, MVC maraviroc, 3TC lamivudine, TDF tenofovir